Morningstar20d
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis ...
pharmaphorum10d
4th ALS Drug Development Summit
The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...
Week99er on MSN1mon
Will Quantum Computing Threaten Blockchain Security?
Quantum Resistant Ledger (QRL) serves as a prime example of blockchain projects that operate under quantum-proof encryption ...
ALS News Today11d
QRL-101 reduces motor neuron excitability in healthy volunteers
QRL-101 is designed to open Kv7.2/7.3 ion channels, which work as gates for potassium in nerve cells and help control their ...
Yahoo Finance19d
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis Corporation ...
Pharmabiz18d
QurAlis announces positive data from phase 1 trial of QRL-101 evaluating biomarkers of ALS and epilepsy in healthy volunteers
The decrease in SDTC observed with QRL-101 in this study was approximately 50% greater than previously reported for the Kv7 potassium channel opener ezogabine in a single-dose study in people with ALS ...